Gritstone bio rises on $433 mln US contract for COVID vaccine study

Gritstone bio

27/09/2023 22:22

** Shares of vaccine developer Gritstone bio Inc  GRTS.O 
rise 40.34% to $1.67 after the bell
    ** Co secured a $433 million contract by the U.S. government
to conduct a mid-stage study of its self-amplifying mRNA
COVID-19 vaccine candidate
    ** The study will compare the efficacy, safety and
immunogenicity of co's COVID-19 vaccine candidate with an
approved vaccine
   ** Co plans to initiate the mid-stage study in Q1 2024
    ** The contract is a part of "Project NextGen," an
initiative by the U.S. Department of Health and Human Services
to advance a pipeline of new, innovative vaccines and
therapeutics for protection against COVID-19 infection
    ** GRTS stock down ~65% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))